Advice

following a resubmission:

aprepitant (Emend®) is not recommended for use within NHS Scotland.

Indication under review: As part of combination therapy, for prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy.
Compared with a control regimen, aprepitant has been shown to increase the proportion of patients achieving a complete response in a study of breast cancer patients or experiencing no vomiting in patients with a range of tumour types, when patients were initiated on their first cycle of a moderately emetogenic chemotherapy regimen. However the control regimen was considered suboptimal for the treatment of delayed symptoms and evidence for use in subsequent cycles is limited.

Overall the submitting company did not present sufficiently robust clinical and economic analyses to gain acceptance by SMC.
 

Download detailed advice138KB (PDF)

Download

Medicine details

Medicine name:
aprepitant (Emend)
SMC ID:
242/06
Indication:
As part of combination therapy, for prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy.
Pharmaceutical company
MSD
BNF chapter
Central nervous system
Submission type
Resubmission
Status
Not recommended
Date advice published:
07 November 2011